-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lianhua Qing plague products for the national basic drug catalog and national health insurance catalogue (Class A) varieties, mainly used for cold, influenza-related diseases treatment.
announcement, Lianhua Qing plague products have been repeatedly by the National Health And Health Commission, the State Administration of Traditional Chinese Medicine included in the cold, influenza-related disease diagnosis and treatment program.
2020 Lianhua Qing plague capsules/particles are listed as the National Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "new coronavirus pneumonia diagnosis and treatment program" (trial 4/5/6/7/8 version) recommended medication.
April 12, 2020, the State Drug Administration approved lianhua Qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light, common type" on the basis of the original approved adaptation.
2019, The company achieved operating income of 1.703 billion yuan, accounting for 29.24% of its total operating income.
the first three quarters of 2020, Lianhua Qing plague products achieved operating income of 2.871 billion yuan, accounting for 44.52 percent of total operating income.
